Dyslipidemia, statins and prostate cancer

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA. In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.

Original languageEnglish (US)
Pages (from-to)981-990
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number7
StatePublished - Jul 1 2012


  • dyslipidemia
  • HMG-CoA reductase inhibitors
  • metabolic syndrome
  • prostate cancer
  • statins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'Dyslipidemia, statins and prostate cancer'. Together they form a unique fingerprint.

Cite this